Fundraising Fox
/Companies
Sign in

Xencor

NASDAQ: XNCR

Monrovia, US · Delaware corporation

Find your way into Xencor

Sign up to see every warm intro you have to Xencor

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the Xencor team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Sign up with GoogleAlready have an account? Log in

Xencor develops antibody-based therapeutics using its XmAb protein engineering platform, with a pipeline focused on treating cancer and other serious diseases. The company is a publicly traded biotechnology firm that engineers Fc domains and bispecific antibodies and partners with other companies to develop and market drugs.

BiotechMedical Devices

Founders & leadership

BIBassil I. Dahiyat
Bassil I. DahiyatDirector, President and Chief Executive Officer
AYAllen Yang
Allen YangExecutive
JK
John KuchExecutive
RR
Richard RanieriNamed on SEC filing
JD
John DesjarlaisNamed on SEC filing
CE
Celia EckertNamed on SEC filing

Board

YH
Yujiro HataBoard director
KG
Kurt GustafsonBoard director
EF
Ellen FeigalBoard director
KG
Kevin GormanBoard director
DR
Dagmar Rosa-BjorkesonBoard director
AB
A. Bruce MontgomeryBoard director

Reported raises · per SEC filings

Form D private placements

$25M disclosed across 1 of 5 rounds · 1900–2021

▶$25MraisedNov 2021 · 1 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Bassil DahiyatExecutive Officer, Director
  • Richard RanieriDirector
  • Yujiro HataDirector
  • Kurt GustafsonDirector
  • Allen YangExecutive Officer
  • Ellen FeigalDirector
  • John DesjarlaisExecutive Officer
  • Celia EckertExecutive Officer
  • John KuchExecutive Officer
  • Kevin GormanDirector
  • Dagmar Rosa-BjorkesonDirector
  • A. Bruce MontgomeryDirector
Offering amount
$25M
Amount sold
$25M
First sale
Nov 2021
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Frequently asked questions

What does Xencor do?
Xencor develops antibody-based therapeutics using its XmAb protein engineering platform, with a pipeline focused on treating cancer and other serious diseases. The company is a publicly traded biotechnology firm that engineers Fc domains and bispecific antibodies and partners with other companies to develop and market drugs.
Who founded Xencor?
Xencor was founded by Bassil I. Dahiyat.
How much funding has Xencor raised?
Xencor has disclosed $25M raised across 1 of its 5 known rounds.
Where is Xencor headquartered?
Xencor is headquartered in Monrovia, US.